Iovance Biotherapeutics, Inc. IOVA Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments?
- Iovance Biotherapeutics, Inc. (IOVA) reported accretion (amortization) of discounts and premiums, investments of $1.12M in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Iovance Biotherapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments decreased by 47.8% year-over-year, from $2.15M to $1.12M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments?
- Over 3 years (2021 to 2025), Iovance Biotherapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments has grown at a 6.2% compound annual growth rate (CAGR), from -$6.01M to $7.2M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- Represents the periodic adjustment to the carrying value of investment securities to reflect the amortization of premiums or the accretion of discounts over the life of the instrument. This adjustment aligns the investment's book value with its effective interest rate. It provides insight into the company's treasury management and the yield profile of its cash equivalents.